Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Ali imajo tarčna zdravila svoje mesto v radiokemoterapiji tumorjev prebavil?
Authors:ID Velenik, Vaneja (Author)
Files:.pdf PDF - Presentation file, download (398,59 KB)
MD5: FDA24349B0B7F2D99A365757E16DE79E
PID: 20.500.12556/dirros/2042676f-dc08-4dd6-9e97-a05f8bc1a7be
 
Language:Slovenian
Typology:1.08 - Published Scientific Conference Contribution
Organization:Logo OI - Institute of Oncology
Abstract:V zadnjem desetletju smo priča hitremu napredku v razumevanju tumorske biologije in imunologije rakov prebavil. Sočasno je prišlo do izboljšav v tehnikah obsevanja, zaradi katerih je lokalna kontrola bolezni boljša, saj je lahko doza na tumor večja, toksičnost na zdrava tkiva pa manjša. Skrb zbujajoč pa ostaja visok delež pojava oddaljenih zasevkov, kar nakazuje na potrebo po še agresivnejšem multimodalnem zdravljenju. Pričakovana dobrobit tarčnih zdravil pri nemetastatskih rakih prebavil je še vedno stvar kliničnih raziskav. Nujna je prepoznava prave populacije bolnikov in vključitev v raziskave ne glede na histologijo ali lokalizacijo tumorjev, pač pa glede na specifične molekularne in genetske nenormalnosti, torej glede na njihov specifični genetski profil.
Keywords:rak požiralnika, rak želodca, radiokemoterapija, rak prebavil
Publication status:Published
Publication version:Version of Record
Year of publishing:2014
Number of pages:str. 48-52, 75
Numbering:Letn. 18, št. 1
PID:20.500.12556/DiRROS-8632 New window
UDC:616.3-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-3EY9GD9O
COBISS.SI-ID:1807739 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:2995
Downloads:739
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013
Publisher:Onkološki inštitut
COBISS.SI-ID:1807227 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:[Do target drugs have its place in radiochemotherapy of gastrointestinal tumours?]
Abstract:In the last decade, we have been witnessing a rapid development of the understanding of tumour biology and immunology of gastrointestinal cancers. Simultaneously, there have been great improvements in radiation techniques, which have subsequently improved local disease control by enabling a larger dose on the tumour and reducing toxicity on healthy tissues. However, a high share of the occurrence of distant metastases remains of great concern, since it indicates the need for an even more aggressive multi-modal treatment. The expected benefit of target drugs in non-metastatic gastrointestinal cancers is still subject to clinical research. It is necessary to identify the right population of patients and include them in research, regardless of the histology or localisation of the tumours but based on specific molecular and genetic abnormalities, thus based on their specific genetic profile.


Archive

niGradiv

Back